[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Kane SV, Karpate AA, Bal M, Juvekar SL, Pai PS: Chemotherapy-induced neuronal maturation in sinonasal teratocarcinosarcoma--a unique observation. Head Neck Pathol; 2009 Mar;3(1):31-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-induced neuronal maturation in sinonasal teratocarcinosarcoma--a unique observation.
  • We report the first case of a SNTCS in 23 year old male treated with neo-adjuvant chemotherapy followed by cranio-facial resection.
  • The patient presented with a short history of nasal obstruction, epistaxis and headache.
  • On imaging, a bone destroying lesion of left paranasal sinuses and nasal cavity was identified.
  • The diagnosis of SNTCS could be offered only on the third biopsy which showed heterogeneous admixture of primitive neuroectodermal, epithelial and mesenchymal elements.
  • Tumor was excised after 4 cycles of neo-adjuvant chemotherapy.
  • The undifferentiated neuroectodermal cells were completely absent in the post chemotherapy specimen.
  • This case throws light on the morphologic evidence of chemotherapy induced maturation in the neuroectodermal component within SNTCS, an event hitherto not reported in the literature in case of SNTCS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / pathology. Cell Differentiation / drug effects. Neurons / pathology. Nose Neoplasms / pathology. Teratocarcinoma / pathology
  • [MeSH-minor] Biomarkers, Tumor. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Humans. Immunohistochemistry. Male. Neoadjuvant Therapy. Neoplasm Staging. Otorhinolaryngologic Surgical Procedures. Radiotherapy. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 1988;45(3):148-52 [3368191.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Mar;112(3):496-500 [7870460.001]
  • [Cites] Hum Pathol. 1998 Jul;29(7):718-22 [9670829.001]
  • [Cites] Ann Diagn Pathol. 2006 Dec;10(6):339-42 [17126251.001]
  • [Cites] Ann Diagn Pathol. 2008 Dec;12(6):415-25 [18995206.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2002 Feb 1;62(2):159-64 [11788149.001]
  • [Cites] Pathology. 1983 Oct;15(4):413-9 [6674870.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):687-91 [15390296.001]
  • [Cites] Cancer. 1968 Apr;21(4):714-21 [5651269.001]
  • [Cites] Cancer. 1976 Aug;38(2):818-23 [974998.001]
  • [Cites] J Surg Oncol. 1977;9(1):21-8 [839794.001]
  • [Cites] Cancer. 1984 May 15;53(10):2140-54 [6322958.001]
  • [Cites] Pathol Int. 2001 Dec;51(12):942-7 [11844067.001]
  • (PMID = 20596986.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2807528
  • [Keywords] NOTNLM ; Neo-adjuvant chemotherapy / Neuronal maturation / Sinonasal tumours / Teratocarcinosarcoma
  •  go-up   go-down


2. Cimino L, Chan CC, Shen D, Masini L, Ilariucci F, Masetti M, Asioli S, Sartori A, Cappuccini L: Ocular involvement in nasal natural killer T-cell lymphoma. Int Ophthalmol; 2009 Aug;29(4):275-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular involvement in nasal natural killer T-cell lymphoma.
  • CASE REPORT: In March 2005 the patient presented with a maxillary sinusitis and upper nasal obstruction.
  • In July she underwent a nasal computed tomography (CT) scan and multiple biopsies of the granulomatous tissue in the nasal fossae.
  • The diagnosis was NK/T non-Hodgkin's lymphoma nasal type, stage IV A.
  • In September after the diagnosis of lymphoma the patient underwent a bone marrow biopsy and thoracic and abdominal CT scan.
  • In October she started chemotherapy cycles.
  • RESULTS: A diagnosis of T-lymphoma cells in the vitreous was made; the tumor was most likely originating from her paranasal NKTL.
  • CONCLUSIONS: Nasal and paranasal sinus lymphomas are rare, but aggressive diseases with a tendency to invade tissues and spread to CNS, including the eye.
  • Ocular manifestations prior to systemic ones may be useful to monitor the response to therapy.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Fatal Outcome. Female. Fundus Oculi. Humans. Middle Aged. Neoplasm Invasiveness. Prednisone / therapeutic use. Recurrence. Uveitis / etiology. Vincristine / therapeutic use. Vitreous Body / pathology

  • MedlinePlus Health Information. consumer health - Eye Care.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1984 Jun;81(6):721-7 [6547270.001]
  • [Cites] Cancer Control. 2004 Sep-Oct;11(5):285-95 [15377987.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Feb;11(2):357-64 [3882644.001]
  • [Cites] Am J Clin Oncol. 1992 Jun;15(3):222-5 [1590274.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):843-9 [8334638.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1994 Nov;103(11):911-4 [7979008.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1474-83 [8608238.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1996 Feb;234(2):137-9 [8720685.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):477-88 [9241082.001]
  • [Cites] Hematol Oncol. 1997 May;15(2):71-9 [9375032.001]
  • [Cites] Ophthalmology. 1998 Aug;105(8):1430-41 [9709754.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2005 May;243(5):482-6 [15586289.001]
  • [Cites] Histopathology. 2005 Nov;47(5):523-32 [16242001.001]
  • [Cites] Leuk Lymphoma. 2005 Dec;46(12):1721-7 [16263574.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Am J Ophthalmol. 2002 Sep;134(3):406-10 [12208253.001]
  • [Cites] Ophthalmology. 1984 Jun;91(6):635-54 [6235470.001]
  • (PMID = 18438613.001).
  • [ISSN] 1573-2630
  • [Journal-full-title] International ophthalmology
  • [ISO-abbreviation] Int Ophthalmol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 EY000222-22
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Other-IDs] NLM/ NIHMS55130; NLM/ PMC2714878
  •  go-up   go-down


3. Karcioglu ZA, Hadjistilianou D, Rozans M, DeFrancesco S: Orbital rhabdomyosarcoma. Cancer Control; 2004 Sep-Oct;11(5):328-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although rhabdomyosarcoma (RMS) is a rare tumor among the entire group of mesenchymal malignancies, it is a relatively common lesion and significant challenge for the ocular oncologist in terms of its diagnosis and management.
  • The tumor has predilection for the superior nasal quadrant of the orbit.
  • The common histopathologic types are embryonal and alveolar varieties.
  • Particular attention should be placed on the bone invasion and extension of the tumor into the intracranial cavity and paranasal sinuses.
  • Treatment usually consists of a combination of chemotherapy and radiation therapy following excisional biopsy.
  • CONCLUSIONS: Survival of orbital RMS has improved due to advances in chemotherapy and radiotherapy.
  • [MeSH-major] Eye Neoplasms / diagnosis. Eye Neoplasms / therapy. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Neoplasm Staging. Ophthalmologic Surgical Procedures / methods. Prognosis. Radiotherapy / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15377992.001).
  • [ISSN] 1526-2359
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 42
  •  go-up   go-down


Advertisement
4. Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG: Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant; 2008 Jul;14(7):741-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is no uniform standard therapy for PTCL, and autologous hematopoietic cell transplant (AHCT) is often offered as consolidation in first remission or at relapse because of the poor outcomes with conventional therapy.
  • Fifty-three cases were identified consisting of systemic anaplastic large cell (n = 18), PTCL unspecified (n = 17), angioimmunoblastic (n = 9), nasal type extranodal NK/T (n = 7), hepatosplenic (n = 2), and adult T cell leukemia/lymphoma (n = 1).
  • Histology, age, sex, stage, B symptoms, bone marrow involvement, and duration of first response did not significantly affect PFS or OS.
  • Based on these results, AHCT as consolidation therapy in first complete or partial response may offer a durable survival benefit.
  • However, AHCT with conventional salvage chemotherapy has minimal durable benefit in patients with relapsed or refractory PTCL, and thus novel strategies and/or allogeneic HCT should be more aggressively explored in lieu of AHCT for relapsed/ refractory PTCL.

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol J. 2004;5(4):304-11 [15297846.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(5):443-50 [17589529.001]
  • [Cites] J Clin Oncol. 1986 Nov;4(11):1628-37 [3772416.001]
  • [Cites] Blood. 1995 Jun 1;85(11):3334-41 [7538824.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Bone Marrow Transplant. 1999 Jul;24(2):153-61 [10455343.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Bone Marrow Transplant. 2001 Apr;27(7):711-6 [11360110.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):978-85 [12648067.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2172-6 [15169805.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jul;12(7):703-11 [16785059.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):202-7 [16759221.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):439-47 [17233846.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):652-7 [17229774.001]
  • [Cites] Ann Hematol. 2007 Jun;86(6):435-42 [17256144.001]
  • [Cites] Eur J Haematol. 2007 Jul;79(1):32-8 [17598836.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(3):239-43 [17530000.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1067-74 [17640855.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2261-7 [15512815.001]
  • (PMID = 18541192.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA049605-15; United States / NCI NIH HHS / CA / P01 CA049605; United States / NCI NIH HHS / CA / P01 CA049605-15
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS232367; NLM/ PMC2980839
  •  go-up   go-down


5. Vergani F, Pirola E, Fiori L, Pagni F, Parmigiani F, Sganzerla EP: Combined transcranial and endoscopic nasal resection for esthesioneuroblastoma. Technical note. J Neurosurg Sci; 2007 Jun;51(2):99-102
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined transcranial and endoscopic nasal resection for esthesioneuroblastoma. Technical note.
  • Esthesioneuroblastoma is a rare malignant neoplasm arising in the nasal cavity.
  • Because of the invasiveness and potentially disfiguring results of a transfacial approach, a new technique has been proposed, combining endoscopic nasal and anterior craniotomy resection.
  • We describe the case of a young male presenting with a large esthesioneuroblastoma involving the nasal cavity and the anterior cranial fossa, causing a huge skull base destruction.
  • A combined transcranial and endoscopic nasal resection resulted in a macroscopically total removal of the tumor.
  • [MeSH-major] Cranial Fossa, Anterior / surgery. Endoscopy / methods. Esthesioneuroblastoma, Olfactory / surgery. Nasal Cavity / surgery. Neurosurgical Procedures / methods. Nose Neoplasms / surgery
  • [MeSH-minor] Adult. Blood Coagulation Disorders. Cranial Sinuses / pathology. Craniotomy / methods. Ethmoid Bone / pathology. Ethmoid Bone / surgery. Humans. Magnetic Resonance Imaging. Male. Nasal Septum / surgery. Nasal Septum / transplantation. Olfactory Mucosa / pathology. Postoperative Hemorrhage / drug therapy. Postoperative Hemorrhage / prevention & control. Reconstructive Surgical Procedures / methods. Surgical Flaps. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17571044.001).
  • [ISSN] 0390-5616
  • [Journal-full-title] Journal of neurosurgical sciences
  • [ISO-abbreviation] J Neurosurg Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


6. Yariş N, Kutluk T, Yalçin B, Akyüz C, Büyükpamukçu M: Nasal-paranasal-oronasopharyngeal lymphomas in childhood: the role of staging system on prognosis. Pediatr Hematol Oncol; 2000 Jul-Aug;17(5):345-53
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal-paranasal-oronasopharyngeal lymphomas in childhood: the role of staging system on prognosis.
  • Most of the patients with nasal-paranasal and oropharyngeal-nasopharyngeal (NPONP) lymphomas had early-stage disease according to the Murphy system.
  • Treatment results were analyzed to see the effects of the staging in NPONP lymphomas.
  • The Murphy staging system was used at diagnosis and all cases were restaged according to the TNM system: primary tumor, regional lymph node, and metastasis.
  • The survival rates were analyzed by grouping the patients according to the treatment and stages.
  • Treatment protocols were intensified in most of the early-stage disease treated with modified LSA2-L2 regimen and better survival rates were obtained in these patients.
  • The intensification of the treatment by using intrathecal treatment and doxorubicin in patients with early-stage disease at NPONP location seems effective.
  • It should be revised to predict the prognosis and decision-making for treatment.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Nose Neoplasms / diagnosis. Pharyngeal Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Neoplasms / secondary. Central Nervous System Neoplasms / secondary. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Daunorubicin / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Methotrexate / administration & dosage. Nasopharyngeal Neoplasms / diagnosis. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / pathology. Neoplasm Staging. Oropharyngeal Neoplasms / diagnosis. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / pathology. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / pathology. Prednisone / administration & dosage. Prognosis. Recurrence. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Hematol Oncol. 2000 Oct-Nov;17(7):517-20 [11033725.001]
  • (PMID = 10914044.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; LSA2-L2 protocol
  •  go-up   go-down


7. Kainuma K, Netsu K, Asamura K, Hayashi K, Takumi Y, Ota H, Usami S: Chondrosarcoma of the nasal septum: A case report. Auris Nasus Larynx; 2009 Oct;36(5):601-5
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chondrosarcoma of the nasal septum: A case report.
  • Chondrosarcoma make up only 10-20% of malignant primary bone tumors, with 5-10% located in the head and neck (Downey TJ, Clark SK, Moore DW.
  • Chondrosarcoma of the nasal septum.
  • Otolaryngol Head Neck Surg 2001;125:98-100), and nasal septal chondrosarcoma is extremely rare.
  • Surgical excision is the only curative treatment and radiation and chemotherapy have a limited role for palliation.
  • We used a navigation system in endoscopic surgery without complications for a case of chondrosarcoma of the nasal septum by means of a midfacial degloving approach at primary operation and an external incision approach at salvage operation for local recurrence.
  • We discuss the clinical presentation, diagnosis, and treatment of this case as well as present a review of the literature.
  • [MeSH-major] Chondrosarcoma / diagnosis. Chondrosarcoma / surgery. Endoscopy. Nasal Septum. Nose Neoplasms / diagnosis. Nose Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Surgery, Computer-Assisted. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282118.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 14
  •  go-up   go-down


8. Sakamoto E, Yamane T, Nakane T, Takeoka Y, Hirose A, Hagihara K, Nakamae H, Ohta K, Hirayama M, Ikura Y, Ohsawa M, Sawada T, Kitoh T, Hino M: [Temporary effective treatment with L-asparaginase for a patient with refractory nasal NK/T-cell lymphoma]. Gan To Kagaku Ryoho; 2005 Nov;32(12):1993-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Temporary effective treatment with L-asparaginase for a patient with refractory nasal NK/T-cell lymphoma].
  • A 48-year-old man was referred to Sakai Municipal Hospital with nasal discharge and right facial swelling.
  • The pathological findings of a nasal cavity tumor revealed stage IIB NK/T-cell lymphoma.
  • He was admitted to our hospital and received CHOP therapy, resulting in progressive disease.
  • Irradiation therapy combined with DeVIC chemotherapy also could not shrink his lymphoma.
  • Then, two courses of L-asparaginase(L-Asp) were administered, resulting in partial improvement of the nasal and pharynx lesions, resolution of the fever and improvement of his performance status.
  • On the day before a third course of L-Asp, he again developed a lowgrade fever.
  • Post-mortem examinations revealed hemophagocytosis in the bone marrow and liver, and infiltration of lymphoma cells into multiple organs including left lower lung, liver, spleen and kidneys.
  • Although L-Asp was effective against nasal NK/T-cell lymphoma resistant to combination chemotherapy and irradiation therapy, the effectiveness of the single agent with L-Asp was only transient.
  • L-Asp based regimen should be used as first-line therapy if asparagine synthetase protein expression is low using an immunohistochemical method.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Asparaginase / therapeutic use. Lymphoma, T-Cell / drug therapy. Nose Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Drug Administration Schedule. Fatal Outcome. Humans. Kidney Neoplasms / pathology. Liver Neoplasms / pathology. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282743.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


9. Pagano L, Gallamini A, Trapè G, Fianchi L, Mattei D, Todeschini G, Spadea A, Cinieri S, Iannitto E, Martelli M, Nosari A, Bona ED, Tosti ME, Petti MC, Falcucci P, Montanaro M, Pulsoni A, Larocca LM, Leone G, Intergruppo Italiano Linfomi: NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey. Ann Oncol; 2006 May;17(5):794-800
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey.
  • OBJECTIVE: To evaluate the clinical characteristics and outcome of NK/T-cell lymphoma 'nasal type' developed in Italian patients.
  • PATIENTS: Between 1997 and 2004, 26 new cases of NK/T-cell lymphoma 'nasal type' were diagnosed in 10 Italian Hematology institutions.
  • In 23 cases presentation at the onset was in the nasal cavity or adjacent structures, in two cases the lymphoma onset with skin lesions was followed successively by rhynopharyngeal dissemination, while the remaining case had bone marrow and lymph node involvement followed by oro-pharyngeal involvement.
  • Diagnosis was based on the finding of a NK/T-cell phenotype at the histological and immunophenotypic examination of oropharyngeal or cutaneous lesions.
  • All patients but one were treated with chemotherapy, alone in nine cases or associated to radiotherapy in 14 cases; two patients had chemotherapy, radiotherapy and surgery, while one patient underwent only surgery.
  • Chemotherapy was anthracycline-based in 17 out of 25 cases.
  • In those patients in whom radiotherapy was performed, radiation dosages ranged between 36 Gy and 47.5 Gy, with a median dosage of 40 Gy.
  • Nine patients (34%) were responsive to the treatments: six patients obtained a complete remission and other three a partial remission.
  • The remaining 17 patients resulted refractory or presented a limited response to therapy.
  • The median disease-free survival was 14 months and the median overall survival time was 9 months.
  • CONCLUSION: The results of this retrospective survey confirmed that NK/T-cell lymphoma 'nasal type' is a very rare lymphoma in the Italian population, and it is characterized by a very bad prognosis.
  • Due to the rarity of this disease, a standardized therapeutic approach is lacking.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497823.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Chuang SS, Lin CN, Li CY: Primary bony peripheral T-cell lymphoma mimicking nasal type NK/T-cell lymphoma: a case report. Pathol Res Pract; 2002;198(5):369-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bony peripheral T-cell lymphoma mimicking nasal type NK/T-cell lymphoma: a case report.
  • Natural killer (NK)/T-cell lymphomas are highly aggressive lymphomas of NK- or T-cell lineage with predominant extranodal presentation and are divided into nasal and nasal-type (extra-nasal).
  • We report a primary bony peripheral T-cell lymphoma mimicking NK/T-cell lymphoma, nasal type.
  • A 22-year-old Taiwanese male presented with a frontal skull bone mass noted for 3 weeks, and received craniectomy with tumor removal.
  • Polymerase chain reaction study of formalin-fixed tissue showed clonal rearrangement of the T-cell receptor-gamma chain gene.
  • The diagnosis was peripheral T-cell lymphoma, unspecified subtype.
  • His lymphoma was refractory to chemotherapy, and bony metastases developed in the right iliac bone 2 months later.
  • [MeSH-major] Bone Neoplasms / pathology. Killer Cells, Natural / pathology. Lymphoma, T-Cell, Peripheral / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Biomarkers, Tumor / analysis. Clone Cells. DNA, Neoplasm / genetics. Diagnosis, Differential. Fatal Outcome. Frontal Bone / pathology. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Humans. Male. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12092774.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


11. Stokkermans-Dubois J, Jouary T, Vergier B, Delaunay MM, Taieb A: A case of primary cutaneous nasal type NK/T-cell lymphoma and review of the literature. Dermatology; 2006;213(4):345-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary cutaneous nasal type NK/T-cell lymphoma and review of the literature.
  • This article describes a new case of primary cutaneous natural killer/T-cell lymphoma of nasal type (NKTL-NT) and reviews 18 other cases of this rare neoplasm.
  • A comprehensive workup including CT scan and bone marrow biopsy was negative and a diagnosis of NKTL-NT with a primary cutaneous involvement was made.
  • The patient was free of disease under multi-agent chemotherapy after 24 months of follow-up.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell, Cutaneous / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antigens, CD45 / analysis. Antigens, CD56 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Follow-Up Studies. Humans. Leg. Lymphedema / diagnosis. Male

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • (PMID = 17135744.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD56; EC 3.1.3.48 / Antigens, CD45
  • [Number-of-references] 12
  •  go-up   go-down


12. Haresh KP, Prabhakar R, Anand Rajan KD, Sharma DN, Julka PK, Rath GK: A rare case of paraganglioma of the sella with bone metastases. Pituitary; 2009;12(3):276-9
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of paraganglioma of the sella with bone metastases.
  • The patient is a 17-year-old man who developed headache, visual blurring, and diplopia.
  • Trans-nasal trans-sphenoid biopsy showed features of paraganglioma.
  • Four months after treatment he developed bone metastases which was palliated by radiation, zoledronic acid, and chemotherapy.
  • This is the first case of sellar paraganglioma showing metastases to bone.
  • [MeSH-major] Bone Neoplasms / secondary. Paraganglioma / diagnosis. Paraganglioma / pathology. Sella Turcica / pathology
  • [MeSH-minor] Adolescent. Humans. Magnetic Resonance Imaging. Male. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurg Rev. 2003 Jul;26(3):210-4 [12690532.001]
  • [Cites] Clin Neuropathol. 2006 Sep-Oct;25(5):221-6 [17007444.001]
  • [Cites] Acta Neurochir (Wien). 2006 Dec;148(12 ):1311-4; discussion 1314 [17039304.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Oct;34(5):829-36, v [11557441.001]
  • [Cites] Laryngoscope. 1993 Nov;103(11 Pt 2 Suppl 60):7-15 [8231596.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):49-52 [11763422.001]
  • [Cites] Arch Pathol Lab Med. 1999 May;123(5):429-32 [10235503.001]
  • [Cites] Neuroradiology. 1998 Apr;40(4):233-7 [9592793.001]
  • [Cites] Neurosurgery. 1996 Feb;38(2):395-9 [8869071.001]
  • [Cites] Neurosurgery. 1993 May;32(5):844-7 [8492863.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Oct;34(5):837-44, v [11557442.001]
  • [Cites] Tumori. 1998 May-Jun;84(3):408-11 [9678627.001]
  • [Cites] Arch Pathol Lab Med. 1978 Feb;102(2):95-8 [341846.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):265-7 [15980978.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Oct;34(5):845-62, v-vi [11557443.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 Sep-Oct;14 (5):1191-3 [8237702.001]
  • (PMID = 18320326.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Tomita N, Kanamori H, Fujimaki K, Fujisawa S, Ishigatsubo Y: Epstein-Barr virus-associated extranodal NK/T-cell lymphoma following mosquito bites in an elderly patient without prior hypersensitivity. Leuk Lymphoma; 2004 Oct;45(10):2153-5
MedlinePlus Health Information. consumer health - Insect Bites and Stings.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a 73-year-old woman who developed fever and inflammation with ulceration at the site of mosquito bites in the lower thigh.
  • Soon she developed disseminated skin lesions characterized by redness, induration, and local heat.
  • Some lesions showed necrosis and ulceration, including those located in the nasal cavity.
  • A skin biopsy specimen from the lower thigh adjoining the mosquito bites was diagnosed pathologically as showing extranodal NK/T cell lymphoma, nasal type.
  • Bone marrow examination revealed infiltration by lymphoma cells and marked hemophagocytosis.
  • The patient underwent three cycles of chemotherapy with carboplatin, etoposide, ifosfamide, and dexamethasone (DeVIC), but died of lymphoma progression during treatment.
  • [MeSH-minor] Aged. Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Examination. Bone Marrow Neoplasms. Culicidae. Fatal Outcome. Female. Humans. Neoplasm Invasiveness. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Allergy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15370264.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Matsumoto Y, Nomura K, Kanda-Akano Y, Fujita Y, Nakao M, Ueda K, Horiike S, Yokota S, Kusuzaki K, Kitoh T, Watanabe A, Taniwaki M: Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma; 2003 May;44(5):879-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma.
  • A 38-year-old male patient with ulcerated tumor at the left thigh was diagnosed as having nasal type NK/T cell lymphoma on the basis of histopathological and flowcytometric findings of tumor, revealing diffuse infiltration of atypical lymphoid cells into blood vessels and expression of CD7 and CD56 antigens, but not CD3.
  • He had tumor infiltration in the bone marrow and at the right lower lung field.
  • After five cycles of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) therapy, the patient achieved complete remission and received high-dose chemotherapy with auto-PBSCT, although the tumor recurred in the right leg 10 months later.
  • Despite salvage chemotherapy, followed by local irradiation and surgical amputation, a tumor recurred at the left upper gingiva 10 days after.
  • The asparagine synthetase expression in tumor cells was immunohistochemically negative on paraffin-embedded tissues.
  • L-asparaginase is a promising agent for the treatment of NK/T cell lymphoma.
  • [MeSH-major] Asparaginase / administration & dosage. Killer Cells, Natural / pathology. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adult. Anaphylaxis / chemically induced. Erwinia / enzymology. Escherichia coli Proteins / adverse effects. Humans. Male. Neoplasm Invasiveness / pathology. Peripheral Blood Stem Cell Transplantation. Recurrence. Remission Induction / methods. Treatment Outcome

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12802930.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Escherichia coli Proteins; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


15. Hornick JL, Jaffe ES, Fletcher CD: Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol; 2004 Sep;28(9):1133-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histiocytic sarcoma is a rare malignant neoplasm that occurs in lymph nodes, skin, and the gastrointestinal tract.
  • Seven tumors arose in soft tissue (6 lower limb; 1 upper limb), 5 in the gastrointestinal tract (1 involving both stomach and colon, 1 ileum, 2 rectum, 1 anus), 1 in the nasal cavity, and 1 in the lung.
  • Six patients were treated with postoperative radiation and 7 with chemotherapy (CHOP or ProMACE-MOPP).
  • Two tumors recurred locally, and 5 patients developed distant spread: 3 to lymph nodes, 1 to lung, and 1 to bone.
  • At the last follow-up, 2 patients have died of disseminated disease, 4 and 5 months following initial diagnosis.
  • Histiocytic sarcoma may arise primarily in soft tissue and shows reproducible histologic features, including abundant eosinophilic cytoplasm and a prominent inflammatory infiltrate.

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15316312.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Lee N, Xia P, Fischbein NJ, Akazawa P, Akazawa C, Quivey JM: Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys; 2003 Sep 1;57(1):49-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation.
  • PURPOSE: To review the University of California-San Francisco (UCSF) experience of using intensity-modulated radiation therapy (IMRT) to treat head-and-neck cancer focusing on the importance of target volume delineation and adequate target volume coverage.
  • Sites included were nasopharynx 86, oropharynx 22, paranasal sinus 22, thyroid 6, oral tongue 3, nasal cavity 2, salivary 2, larynx 2, hypopharynx 1, lacrimal gland 1, skin 1, temporal bone 1, and trachea 1.
  • One hundred seven patients were treated definitively with IMRT +/- concurrent platinum chemotherapy (92/107), whereas 43 patients underwent gross surgical resection followed by postoperative IMRT +/- concurrent platinum chemotherapy (15/43).
  • The average prescription doses to the GTV were 70 Gy and 66 Gy for the primary and the postoperative cases, respectively.
  • The site of recurrence was determined by the diagnostic neuroradiologist to be either within the GTV or the CTV volume by comparison of the treatment planning computed tomography with posttreatment imaging studies.
  • RESULTS: For the primary definitive cases with a median follow-up of 25 months (range 6 to 78 months), 4 patients failed in the GTV.
  • For the primary group, the average maximum, mean, and minimum doses delivered were 80 Gy, 74 Gy, 56 Gy to the GTV, and 80 Gy, 69 Gy, 33 Gy to the CTV.
  • For the postoperative group, the average maximum, mean, and minimum doses delivered were 79 Gy, 71 Gy, 37 Gy to the GTV and 79 Gy, 66 Gy, 21 Gy to the CTV.
  • CONCLUSION: Accurate target volume delineation in IMRT treatment for head-and-neck cancer is essential.
  • Higher treatment failure rates were noted in the postoperative setting in which lower doses were prescribed.
  • [MeSH-major] Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / radiotherapy. Imaging, Three-Dimensional / methods. Neoplasm Recurrence, Local / epidemiology. Radiotherapy Planning, Computer-Assisted / methods
  • [MeSH-minor] Academic Medical Centers. Adolescent. Adult. Aged. Aged, 80 and over. California / epidemiology. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging / methods. Radiotherapy, Conformal / methods. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1639; author reply 1639-40 [15050350.001]
  • (PMID = 12909215.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Nascimento AF, Fletcher CD: Spindle cell rhabdomyosarcoma in adults. Am J Surg Pathol; 2005 Aug;29(8):1106-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The head and neck region, including the oral cavity, parotid gland, nasopharynx, and nasal cavity, was the commonest affected area, accounting for >50% of the cases, followed by retroperitoneum, thigh, leg, subscapular area, hand, vulva, and paratesticular region (1 case each).
  • Treatment modalities included surgery, chemotherapy, and radiation.
  • Two patients died of uncontrolled local disease 13 and 27 months after diagnosis; 4 were alive without disease at 12, 17, 24, and 102 months, including 1 patient with metastasis to 10 of 50 pelvic lymph nodes at presentation; 3 are alive with localized disease at 16, 17, and 19 months; and 1 was followed for 6 months and showed persistent local disease.
  • One patient is alive at 10 months after diagnosis with evidence of metastatic disease to bone, lungs, and breast.
  • Spindle cell RMS is a rare neoplasm in adults and appears to have distinct clinicopathologic features when compared with cases occurring in the pediatric population.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006807.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Desmin; 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / Myogenic Regulatory Factors; 0 / Myoglobin; 0 / S100 Proteins; 0 / myogenic factor 6; 68238-35-7 / Keratins; EC 3.6.4.1 / Myosins
  •  go-up   go-down


18. Raney B, Anderson J, Breneman J, Donaldson SS, Huh W, Maurer H, Michalski J, Qualman S, Ullrich F, Wharam M, Meyer W, Soft-Tissue Sarcoma Committee of the Children's Oncology Group, Arcadia, California, USA: Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology Group. Pediatr Blood Cancer; 2008 Jul;51(1):17-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The 54 males and 37 females were <1-19 years at diagnosis.
  • Primary sites were nasopharynx-nasal cavity, middle ear/mastoid and parapharyngeal area ("better" sites, 55%), paranasal sinus and infratemporal-pterygopalatine area ("worse" sites, 42%), and other (3%).
  • Major metastatic sites at diagnosis were lung (63%), bone marrow (33%), and bone (27%).
  • Treatment included vincristine, actinomycin D, and cyclophosphamide (VAC) chemotherapy and radiotherapy to the primary tumor and up to five metastatic sites/tissues.
  • Sixty patients had progressive disease (N = 49) or death as a first event (N = 11); another developed myelodysplastic syndrome and died.
  • Patients with the best outlook had embryonal RMS located in the nasopharynx/nasal cavity, middle ear/mastoid, or parapharyngeal region.
  • Distant metastases were the most frequent type of recurrence, indicating that more effective systemic agents are needed to eliminate residual disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18266224.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-98543; United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / CA-72989; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA-29511
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


19. Lu TX, Mai WY, Teh BS, Zhao C, Han F, Huang Y, Deng XW, Lu LX, Huang SM, Zeng ZF, Lin CG, Lu HH, Chiu JK, Carpenter LS, Grant WH 3rd, Woo SY, Cui NJ, Butler EB: Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys; 2004 Mar 1;58(3):682-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The average time to the nasopharyngeal recurrence was 30.2 months after initial conventional RT.
  • The median isocenter dose to the nasopharynx was 70 Gy (range 60.9-78.0) for the initial conventional RT.
  • All patients were restaged at the time of recurrence according to the 1992 Fuzhou, China staging system on NPC.
  • Invasion of the nasal cavity, maxillary sinus, ethmoid sinus, sphenoid sinus, and cavernous sinus and erosion of the base of the skull was found in 8, 1, 3, 8, 15, and 20 patients, respectively.
  • The GTV in the nasopharynx and positive lymph nodes in the neck received a prescription dose of 68-70 Gy and 60 Gy, respectively.
  • Three patients who had positive lymph nodes were treated with five to six courses of chemotherapy (cisplatin + 5-fluorouracil) after IMRT.
  • RESULTS: The treatment plans showed that the percentage of GTV receiving 95% of the prescribed dose (V(95-GTV)) was 98.5%, and the dose encompassing 95% of GTV (D(95-GTV)) was 68.1 Gy in the nasopharynx.
  • The mean dose to the GTV was 71.4 Gy.
  • Three patients developed metastases at a distant site: two in the bone and one in the liver and lung at 13 months follow-up.
  • Acute toxicity (skin, mucosa, and xerostomia) was acceptable according to the Radiation Therapy Oncology Group criteria.
  • The treatment-related toxicity profile was acceptable.
  • In contrast to primary NPC, recurrent NPC reirradiated with high-dose IMRT led to the shedding of tumor necrotic tissue toward the end of RT.
  • More patients and longer term follow-up are warranted to evaluate late toxicity and treatment outcome.
  • [MeSH-major] Nasopharyngeal Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy, Conformal / methods

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14967420.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Nasr Ben Ammar C, Ghorbel I, Kochbati L, Gargouri W, Touati S, Maalej M: [Solitary and extramedullary plasmocytoma in the head and neck region: five cases report]. Cancer Radiother; 2010 Dec;14(8):755-8
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Plasmocytome solitaire extramédullaire de la tête et du cou: à propos de cinq cas.
  • Three patients had a solitary plasmocytoma of the nasal fossa; the others were ethmoidal and submandibular node.
  • All patients received irradiation of 40 to 45 Gy in the primary site associated to surgery in four cases.
  • Multiple myeloma occurred in one patient 8 years after treatment.
  • CONCLUSION: Radiotherapy is the best effective local treatment.
  • Local control of extramedullary plasmocytoma in the head and neck region seems to be improved when the dose is at least 45 Gy.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Disease Progression. Ethmoid Bone / pathology. Ethmoid Bone / surgery. Female. Humans. Male. Maxillary Neoplasms / pathology. Maxillary Neoplasms / radiotherapy. Maxillary Neoplasms / surgery. Middle Aged. Multiple Myeloma / drug therapy. Multiple Myeloma / radiotherapy. Neoplasm Invasiveness. Neoplasm Recurrence, Local / radiotherapy. Nose Neoplasms / radiotherapy. Nose Neoplasms / surgery. Remission Induction. Skull Neoplasms / pathology. Skull Neoplasms / radiotherapy. Skull Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20673736.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement